Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.